trending Market Intelligence /marketintelligence/en/news-insights/trending/Sf0HKVLf1k_DRmiTdSaZ5A2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Cardiome Pharma launches skin drug in Germany

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021

Six trends shaping the industries and sectors we cover in 2021


Cardiome Pharma launches skin drug in Germany

Cardiome Pharma Corp. launched the Xydalba skin treatment ahead of schedule in Germany.

The drug is approved by the European Medicines Agency to treat adults with acute bacterial skin and skin structure infections, or ABSSSI. It has already been launched in the U.K.

The drug is planned for further launch in other European countries. The German ABSSSI hospital market is valued at $123 million, according to Datamonitor.